A San Francisco host says a robotics startup booked his Airbnb to test a prototype and left thousands of dollars in damage. He’s now seeking $12,383.50 in small‑claims court.

A Sam Altman‑backed Orb is scanning irises in San Francisco to create World ID credentials as Tinder, Zoom and DocuSign test the system; privacy experts warn the data is permanent.

California sued 23andMe, alleging the company downplayed a 2023 hack that exposed nearly 7 million customers’ genetic data and broke state privacy laws.

Anthropic rolled out Claude Opus 4.8 on May 28, 2026 — a faster, cheaper Claude update with new agentic features, while Mythos remains tightly gated for security.

Webflow made surprise cuts this week; several employees said they were locked out of company accounts before receiving termination emails. CEO Linda Tong framed the move as a pivot toward AI‑driven marketing tools.

An experimental drug called bepirovirsen produced durable 'functional cures' in roughly 20% of patients in large trials, offering a potential finite therapy for chronic hepatitis B.

Gilead’s Hepcludex won FDA accelerated approval on May 22, 2026 — the first U.S. therapy for chronic hepatitis D — as Mirum and Vir push rival candidates toward late‑stage results.

Dropbox founder Drew Houston promoted Ashraf Alkarmi to co‑CEO and will transition to executive chairman as the company leans into AI and product work.

The Supreme Court declined to block Vermont’s consumer‑protection suit accusing Instagram of engineering features that addict teens, allowing the case to proceed. The decision follows recent state court setbacks for Meta.

Oklo says it has been picked by the DOE for talks to turn Cold War plutonium into reactor fuel while critics warn of serious proliferation and safety concerns. The company will partner with newcleo and says strict safeguards would apply.

After a failed flu trial, Marianne De Backer closed labs, cut staff and struck licensing deals that refocused San Francisco’s Vir on hepatitis and cancer. The result is a leaner company with big‑pharma partners.

Modelers have removed the extreme RCP8.5/SSP5‑8.5 marker from the CMIP7 design; the revision narrows the upper‑end of projections but still leaves large warming and financial risk.

Zoom’s Q1 revenue rose 5.5% as AI tools and enterprise products lift growth and management expands buybacks while aiming for larger AI monetization.